I have had patients present with papulopustular lesions on the central face, no comedones, a history of chronic flushing, and a longstanding diagnosis of acne. None of them had acne. They had rosacea. In every case, the missed diagnosis had led to months of treatment that partially helped but never resolved.
In all of those patients, the skin tone was Fitzpatrick type IV or V.
The relationship between rosacea and skin of colour is underrepresented in clinical training. The clinical picture in darker phototypes is genuinely different. Not in the underlying pathophysiology, but in what we can see.
Why the classic presentation misleads
The textbook rosacea diagnosis relies heavily on visible central facial erythema. In Fitzpatrick types IV to VI, this erythema is masked. The vascular component is present, but higher melanin density means erythema reads as a dusky brown or grey discolouration rather than visible redness. If you are looking for red, you will not find it.
This creates a diagnostic gap. Practitioners trained primarily on lighter phototypes may correctly identify that rosacea erythema is not visible. The mistake is concluding that rosacea is therefore absent.
The first visible sign in darker skin is often a papulopustular eruption without obvious background erythema. The surrounding vascular inflammation is present. It is simply not presenting in the way we expect.
Subtype identification when the visual cues are limited
All four rosacea subtypes occur across all Fitzpatrick types. The clinical approach shifts in darker skin.
Erythematotelangiectatic rosacea presents with flushing as the dominant early feature. Flushing is a symptom, not a visible sign. Telangiectasia may be present but is harder to detect clinically. The history becomes your primary diagnostic tool. Ask directly about chronic central face flushing, heat and spice as triggers, prolonged facial warmth following exercise, and skin that reacts to wind or temperature change with lasting sensitivity.
Many patients in Fitzpatrick types IV to VI report flushing episodes they have never connected to a skin condition. When you ask, they describe it clearly. When you do not ask, it stays undisclosed.
Papulopustular rosacea is the most commonly misdiagnosed subtype in skin of colour, most often recorded as acne. The differentiators hold regardless of phototype: no comedones, central facial distribution, absence of a comedonal response to benzoyl peroxide treatment, and a flushing history consistent with erythematotelangiectatic features even when those features were not previously identified.
Phymatous changes, particularly rhinophyma, can present as the initial visible sign in darker skin when earlier features have been missed. The textural thickening and pore changes are visible across all phototypes.
Ocular rosacea occurs in all phototypes and is underdiagnosed across all of them. Ask about chronic eye irritation, lid margin changes, sensitivity to wind, and redness that practitioners have attributed to hay fever or screen use.
The barrier picture
Rosacea involves disrupted barrier function regardless of skin tone. Transepidermal water loss is elevated. Serine protease overactivity drives skin sensitivity and inflammatory signalling. This is consistent across Fitzpatrick types.
In skin of colour, barrier disruption carries an additional concern: post-inflammatory hyperpigmentation. Any intervention that increases local inflammation or compromises the barrier further, including high-strength AHA peels, aggressive resurfacing, or poorly sequenced treatment, raises PIH risk disproportionately.
This is not a reason to avoid treatment. It is a reason to design treatment carefully.
Treatment in skin of colour
Standard topical rosacea treatments are appropriate across all phototypes. Metronidazole and ivermectin address inflammatory and Demodex-related components. Azelaic acid is particularly useful in skin of colour because its mild tyrosinase-inhibiting activity reduces co-existing pigmentation change alongside the primary anti-inflammatory effect. It earns its place in the protocol on both counts.
Avoid high-percentage AHA peels during active treatment phases. PIH risk is disproportionate relative to clinical benefit when inflammation is already present. Reserve any resurfacing work for the stable, controlled phase.
Photoprotection is clinical, not cosmetic. UV exposure and heat both trigger flushing. Tinted broad-spectrum SPF that attenuates visible light provides added protection against pigmentation changes in darker skin and belongs in every rosacea protocol at every stage.
The consultation that compensates for what you cannot see
When you cannot rely on erythema as a visual diagnostic sign, the consultation becomes the instrument.
Ask about flushing duration, frequency, and triggers. Ask about eye symptoms. Ask whether previous acne treatment partially helped but never cleared the central face. Ask about family history, as rosacea has a familial component that patients do not always volunteer.
Document texture, skin sensitivity, papulopustular pattern, and pore changes alongside photographs. Good lighting and a systematic approach to clinical documentation replace the rapid visual diagnosis that lighter skin allows.
Rosacea in skin of colour is not rare. It is under-identified. The consequences of missing it are months of inappropriate treatment, progressive barrier damage, and preventable PIH.
For a complete framework covering rosacea subtype classification, barrier assessment, and treatment design across skin tones, Rosacea Beyond Redness covers the clinical evidence in full at aestheticsunlocked.co.uk/courses/rosacea-beyond-redness.